Janney Montgomery Scott LLC lessened its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 6.0% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 43,926 shares of the company’s stock after selling 2,807 shares during the period. Janney Montgomery Scott LLC’s holdings in Novo Nordisk A/S were worth $2,026,000 as of its most recent filing with the SEC.
A number of other large investors also recently added to or reduced their stakes in NVO. Zions Bancorporation bought a new stake in Novo Nordisk A/S during the first quarter valued at about $137,000. Institutional & Family Asset Management LLC bought a new stake in Novo Nordisk A/S during the first quarter valued at about $156,000. MV Capital Management Inc. bought a new stake in Novo Nordisk A/S during the first quarter valued at about $185,000. Whittier Trust Co. grew its holdings in Novo Nordisk A/S by 61.5% during the first quarter. Whittier Trust Co. now owns 4,040 shares of the company’s stock valued at $199,000 after purchasing an additional 1,538 shares during the period. Finally, Private Capital Group LLC grew its holdings in Novo Nordisk A/S by 2,357.1% during the first quarter. Private Capital Group LLC now owns 4,005 shares of the company’s stock valued at $200,000 after purchasing an additional 3,842 shares during the period. 6.73% of the stock is owned by institutional investors and hedge funds.
A number of research firms have recently weighed in on NVO. Zacks Investment Research lowered Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research note on Thursday, April 12th. Sanford C. Bernstein raised Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research note on Monday, July 2nd. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $64.00.
About Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity.
Read More: Trading Strategy Examples and Plans
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.